Clinical Trial Update: A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia [Phase 3]

View source ↗

Summary

Phase 3 trial updating results for ibrutinib versus ofatumumab in relapsed/refractory CLL and SLL; results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• Ibrutinib (ibrutinib)
• Ofatumumab (ofatumumab)

Snippet

Sponsor: Pharmacyclics LLC. | Conditions: Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | Status: COMPLETED | Results posted: 2015-10-12